Viking Therapeutics (VKTX) stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735.
The deal likely signals Viking isn't open to entertaining a takeover deal in the near future.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?William Blair analyst Andy Hsieh was "enthusiastic" about the deal. CordenPharma, a contract development and manufacturing organization, will be able to fill and pack up to 100 million autoinjectors, 100 million vials and syringes and make more than 1 billion oral tablets.
In turn, Viking will make prepayments amounting to $150 million over the next three years.
"We acknowledge that investors could view the deal as a negative development with respect to Viking's takeout prospects; however, we do not share this view," Hsieh said in a report. "Given the importance of procuring (active pharmaceutical ingredient) and he associated devices and accessories, we argue it would be imprudent to delay such discussions even if Viking was theoretically in late-stage discussions with an acquirer."
But Viking Therapeutics stock slipped more than 6% to 26.12 in early morning trades.
More to follow.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
Want More IBD Insights? Subscribe To Our Investing Podcast!
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。